Starling Oncology, Inc. (STLN) Return on equity 2020–2024
Starling Oncology, Inc. (STLN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-1801.7%FY2024 · since FY2020: -51.0% → -1801.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -1801.7% | -1656.0 pp |
| FY2023 | -145.7% | -145.8 pp |
| FY2022 | 0.1% | +10.6 pp |
| FY2021 | -10.5% | +40.5 pp |
| FY2020 | -51.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More STLN financial trends
STLN RevenueSTLN Net incomeSTLN Net marginSTLN Gross profitSTLN Gross marginSTLN Operating incomeSTLN Operating marginSTLN Operating cash flowSTLN Free cash flowSTLN Capital expendituresSTLN Stock buybacksSTLN Dividends paidSTLN Total assetsSTLN Total liabilitiesSTLN Shareholders’ equitySTLN overview →